This site is intended only for healthcare professionals resident in the Republic of Ireland
Adjusted survival curve of overall drug discontinuation for any reason
|Overall Drug Maintenance 1,f||Hazard Ratio (95% Cl)|
|XELJANZ monotherapy vs XELJANZ combination therapy||1.11 (0.91, 1.35)|
|bDMARD-OMA monotherapy vs bDMARD-OMA combination therapya||1.03 (0.89, 1.20)|
|TNFi combination therapy vs TNFi monotherapy||1.27 (1.08, 1.49)|
|Randomised Controlled Trials (RCTs)1-3 vs Real-World Data Sources 1-3|
|lnterventional design||Observational design|
|Always prospective||Often retrospective|
|Data from prespecified assessment of relatively homogenous patient population selected using well-defined eligibility criteria||Data from routine clinical practice and relevant point-of-care assessments of relatively heterogeneous patient population|
|Patient treatment based on randomised assignment to treatment or control/ comparator groups||
Patient treatment based on prescriber decision (not randomised)
|Bias is controlled by random treatment assignment||A variety of statistical approaches are used to minimize bias|
Learn more about the XELJANZ safety profile
Learn about dosing in RA
Find out more about how XELJANZ works
Legal Category: S1A
Further information is available upon request
Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
Adverse events should also be reported to Pfizer Medical Information on 1800 633 363
Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.
This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie
This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.
Copyright © 2023 Pfizer Limited. All rights reserved.
The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.
I confirm that I am a healthcare professional resident in the Republic of Ireland.*
If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.
PP-UNP-IRL-0176. January 2023